The Radiochemistry Facility is a shared resource that provides Cancer Center investigators with expertise and facilities for the radiolabeling and quality control of molecules of potential interest for molecular imaging in animal models of human cancer as well as cancer radio-diagnosis and targeted radiotherapy. This is a new facility that has evolved from the Radiolabeling Facility to meet the emerging needs within the Cancer Center for PET radiochemistry to provide probes for evaluating tumor biochemistry and receptor biology, monitoring treatment response, expediting the development of novel therapies and personalizing patient treatment protocols. Although the primary function of the past facility - labeling antibodies for research purposes and clinical trials - will still be performed, the major function of the Radiochemistry Facility will be to provide Duke Comprehensive Cancer Center investigators with the most essential positron emitting radiotracers needed for basic and clinical research. Functions of the facility include consultation with investigators to determine optimum radionuclide, targeting vector and radioligand, radiosynthesis, scale up, and quality control of the labeled product. Finally, the Director is available to work with investigators in the preparation of an Investigational New Drug or Radioactive Drug Research Committee Application to permit patient studies with radiolabeled molecules.
Radiolabeled molecules are essential components of molecular imaging and the targeted radiotherapy of cancer;however, highly specialized radiochemistry equipment and expertise are required for their radios-ynthesis, particularly at the levels needed for clinical studies and many research applications. The radiochemistry facility will perform an important core function by providing radiolabeled molecules to cancer center investigators in a cost effective manner.
|McDonnell, Eoin; Crown, Scott B; Fox, Douglas B et al. (2016) Lipids Reprogram Metabolism to Become a Major Carbon Source for Histone Acetylation. Cell Rep 17:1463-1472|
|Liu, Hongliang; Gao, Fengqin; Dahlstrom, Kristina R et al. (2016) A variant at a potentially functional microRNA-binding site in BRIP1 was associated with risk of squamous cell carcinoma of the head and neck. Tumour Biol 37:8057-66|
|Evans, M K; Sauer, S J; Nath, S et al. (2016) X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. Cell Death Dis 7:e2073|
|Pollock, Julie A; Wardell, Suzanne E; Parent, Alexander A et al. (2016) Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer. Nat Chem Biol 12:795-801|
|He, Kevin; Li, Yanming; Zhu, Ji et al. (2016) Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates. Bioinformatics 32:50-7|
|Yuan, Hua; Liu, Hongliang; Liu, Zhensheng et al. (2016) A Novel Genetic Variant in Long Non-coding RNA Gene NEXN-AS1 is Associated with Risk of Lung Cancer. Sci Rep 6:34234|
|Schaal, Jeffrey L; Li, Xinghai; Mastria, Eric et al. (2016) Injectable polypeptide micelles that form radiation crosslinked hydrogels in situ for intratumoral radiotherapy. J Control Release 228:58-66|
|Pilaz, Louis-Jan; Lennox, Ashley L; Rouanet, Jeremy P et al. (2016) Dynamic mRNA Transport and Local Translation in Radial Glial Progenitors of the Developing Brain. Curr Biol 26:3383-3392|
|Matak, Pavle; Matak, Andrija; Moustafa, Sarah et al. (2016) Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice. Proc Natl Acad Sci U S A 113:3428-35|
|Friedman, Daphne R; Sibley, Alexander B; Owzar, Kouros et al. (2016) Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. Am J Hematol 91:687-91|
Showing the most recent 10 out of 443 publications